122 related articles for article (PubMed ID: 26569224)
21. Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia.
Zheng PZ; Wang KK; Zhang QY; Huang QH; Du YZ; Zhang QH; Xiao DK; Shen SH; Imbeaud S; Eveno E; Zhao CJ; Chen YL; Fan HY; Waxman S; Auffray C; Jin G; Chen SJ; Chen Z; Zhang J
Proc Natl Acad Sci U S A; 2005 May; 102(21):7653-8. PubMed ID: 15894607
[TBL] [Abstract][Full Text] [Related]
22. Effect of arsenic trioxide on cytokine expression by acute promyelocytic leukemia cells.
Jiang G; Bi K; Tang T; Zhang Y; Ren H; Jiang F; Ren Q; Zhen G; Liu C; Peng J; Guo G; Liu X; Tian Z
Chin Med J (Engl); 2003 Nov; 116(11):1639-43. PubMed ID: 14642127
[TBL] [Abstract][Full Text] [Related]
23. Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells.
Chen GQ; Zhou L; Styblo M; Walton F; Jing Y; Weinberg R; Chen Z; Waxman S
Cancer Res; 2003 Apr; 63(8):1853-9. PubMed ID: 12702573
[TBL] [Abstract][Full Text] [Related]
24. Relationship between cytokines and leukocytosis in patients with APL induced by all-trans retinoic acid or arsenic trioxide.
Bi KH; Jiang GS
Cell Mol Immunol; 2006 Dec; 3(6):421-7. PubMed ID: 17257495
[TBL] [Abstract][Full Text] [Related]
25. Missense mutations in the PML/RARalpha ligand binding domain in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia.
Marasca R; Zucchini P; Galimberti S; Leonardi G; Vaccari P; Donelli A; Luppi M; Petrini M; Torelli G
Haematologica; 1999 Nov; 84(11):963-8. PubMed ID: 10553155
[TBL] [Abstract][Full Text] [Related]
26. Arsenic trioxide, a therapeutic agent for APL.
Zhang TD; Chen GQ; Wang ZG; Wang ZY; Chen SJ; Chen Z
Oncogene; 2001 Oct; 20(49):7146-53. PubMed ID: 11704843
[TBL] [Abstract][Full Text] [Related]
27. Inhibition factors of arsenic trioxide therapeutic effects in patients with acute promyelocytic leukemia.
Sui M; Zhang Z; Zhou J
Chin Med J (Engl); 2014; 127(19):3503-6. PubMed ID: 25269921
[TBL] [Abstract][Full Text] [Related]
28. Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines.
Davison K; Côté S; Mader S; Miller WH
Leukemia; 2003 May; 17(5):931-40. PubMed ID: 12750708
[TBL] [Abstract][Full Text] [Related]
29. Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia.
Lengfelder E; Hofmann WK; Nowak D
Leukemia; 2012 Mar; 26(3):433-42. PubMed ID: 21904379
[TBL] [Abstract][Full Text] [Related]
30. A facile route to core-shell nanoparticulate formation of arsenic trioxide for effective solid tumor treatment.
Zhang Z; Liu H; Zhou H; Zhu X; Zhao Z; Chi X; Shan H; Gao J
Nanoscale; 2016 Feb; 8(7):4373-80. PubMed ID: 26840759
[TBL] [Abstract][Full Text] [Related]
31. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z
Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642
[TBL] [Abstract][Full Text] [Related]
32. Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: clinicopathological and molecular features of a pilot study.
Kwong YL; Au WY; Chim CS; Pang A; Suen C; Liang R
Am J Hematol; 2001 Apr; 66(4):274-9. PubMed ID: 11279639
[TBL] [Abstract][Full Text] [Related]
33. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies.
Douer D; Tallman MS
J Clin Oncol; 2005 Apr; 23(10):2396-410. PubMed ID: 15800332
[TBL] [Abstract][Full Text] [Related]
34. Dose-adjusted arsenic trioxide for acute promyelocytic leukaemia in chronic renal failure.
Firkin F; Roncolato F; Ho WK
Eur J Haematol; 2015 Oct; 95(4):331-5. PubMed ID: 25600167
[TBL] [Abstract][Full Text] [Related]
35. Apoptosis induction by (+)alpha-tocopheryl succinate in the absence or presence of all-trans retinoic acid and arsenic trioxide in NB4, NB4-R2 and primary APL cells.
Freitas RA; Silva dos Santos GA; Gimenes Teixeira HL; Scheucher PS; Lucena-Araujo AR; Lima AS; Abreu e Lima RS; Garcia AB; Jordão AA; Falcão RP; Vannucchi H; Rego EM
Leuk Res; 2009 Jul; 33(7):958-63. PubMed ID: 19013639
[TBL] [Abstract][Full Text] [Related]
36. Have all-trans retinoic acid and arsenic trioxide replaced all-trans retinoic acid and anthracyclines in APL as standard of care.
Iland HJ; Wei A; Seymour JF
Best Pract Res Clin Haematol; 2014 Mar; 27(1):39-52. PubMed ID: 24907016
[TBL] [Abstract][Full Text] [Related]
37. Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent.
Amadori S; Fenaux P; Ludwig H; O'dwyer M; Sanz M
Curr Med Res Opin; 2005 Mar; 21(3):403-11. PubMed ID: 15811209
[TBL] [Abstract][Full Text] [Related]
38. Signal transduction pathways and transcription factors triggered by arsenic trioxide in leukemia cells.
Sumi D; Shinkai Y; Kumagai Y
Toxicol Appl Pharmacol; 2010 May; 244(3):385-92. PubMed ID: 20193703
[TBL] [Abstract][Full Text] [Related]
39. Arsenic trioxide-induced mitotic arrest and apoptosis in acute promyelocytic leukemia cells.
Cai X; Yu Y; Huang Y; Zhang L; Jia PM; Zhao Q; Chen Z; Tong JH; Dai W; Chen GQ
Leukemia; 2003 Jul; 17(7):1333-7. PubMed ID: 12835721
[TBL] [Abstract][Full Text] [Related]
40. Arsenic trioxide inhibits ATRA-induced prostaglandin E2 and cyclooxygenase-1 in NB4 cells, a model of acute promyelocytic leukemia.
Habib A; Hamade E; Mahfouz R; Nasrallah MS; de Thé H; Bazarbachi A
Leukemia; 2008 Jun; 22(6):1125-30. PubMed ID: 18354491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]